Abstract:Background: Globo series antigens have been implicated in playing important roles in enhancing tumor growth through protecting tumor cells from apoptosis, suppressing T cell activity in the tumor microenvironment and promoting endothelial cell angiogenesis. Globo-H (GH), a globo-series glycosphingolipid (GSL) antigen that is synthesized by key enzymes β1,3-galactosyltransferase V (β3GalT5), fucosyltransferase (FUT) 1 and 2, is highly expressed on a variety of epithelial cancers rendering it a promising target for cancer immunotherapy. GH is reported to associate the EGFR mutant and PD-L1 expression in non-small cell lung cancer (NSCLC) patients. In addition, GH-targeting antibody-drug conjugate (ADC) OBI-999 has been demonstrated an excellent tumor growth inhibition potency in animal models across multiple cancer types including gastric cancer (GC). This study aims to further investigate the GH roles in GC. Methods: Prognostic roles of β3GalT5, FUT1 and FUT2 in GC patients were accessed through the "Kaplan-Meier plotter" database. The level of GH expression was evaluated in clinical adenocarcinoma samples from 105 patients with GC by immunohistochemistry (IHC) using H-score. Microwestern protein array analysis was performed in sorted GC NCI-N87 cells. FACS methods were also employed to measure the levels of PD-L1 and phospho-EGFRs in multiple cancer cell lines. Results: Significant correlations were observed between high mRNA expression of synthesized key enzymes and worse overall survival (OS)/post-progression survival for all 498 GC patients. Positive GH expression (H score≥20; 33.3%) was significantly associated with a poor disease specific survival in all samples (at 15 years; p=0.029), a poor OS in poorly differentiated tumors (p=0.033), and invasiveness (p=0.013), indicating GH expression was a potential prognostic factor in GC. Sorted NCI-N87 cells with high level of endogenous GH expression showed a relatively greater proliferative activity compared with cells expressing low level of GH. Microwestern array analysis on sorted cells indicated upregulations of phospho-AKT/P38/JNK, Cyclin D1 and Cyclin E1 protein in high GH expression NCI-N87 cells, which implicated a mechanistic link between high GH and tumor promoting signals in GC. In addition, GH level was shown to be correlated with cell surface expression level of PD-L1 in NCI-N87, SNU-16, HCC-1428, ACHN, and TKI-resistant H1975 NSCLC cancer cells. Higher phospho-EGFRs (Tyr1068 and Tyr1173) were detected in high GH level of H1975 cells, which is consistent with the results from previous studies showing association between GH level and EGFR mutant/PD-L1 expression in NSCLC. Conclusions: GH level was associated with the survival of GC patients and positively correlated with cell surface PD-L1 expression in vitro. Therefore, GH-targeting therapy has a potential application for the treatment of GC patients. Citation Format: Tzer-Min Kuo, Hui-Ting Hsu, Cheng-Yen Wei, Ming-Tain Lai, Chun-Te Chen. High Globo-H expression associated with poor survival of gastric cancer patients and enriched PD-L1 expression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 6138.

Abstract 5417: PHGDH expression level impacts tumorigenesis and metastasis in human breast cancer

Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma

Abstract B003: Investigating PHLDA2 as a Genetic Driver of Breast Cancer Metastasis

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer

Abstract 5645: HuR regulates aerobic glycolysis in triple negative breast cancer (TNBC)

Abstract B76: High Glucose Induces Breast Cancer Progression Through Upregulating PP2Cδ

Heterogeneity in PHGDH protein expression potentiates cancer cell dissemination and metastasis

Abstract 6654: Association PD-L1 overexpression with immune checkpoint inhibitor effect in triple-negative breast cancer

Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues

Abstract 1452: Hypoxia-induced MIG-6 promotes glucose metabolic reprogramming and tumorigenesis in triple-negative breast cancer

Abstract 3019: The epigenetic factor KDM2B alters the serine-glycine synthesis pathway and the one-carbon metabolism (SGOC) in triple-negative breast cancer

Abstract 6429: Critical role of elevated TMEM176B gene expression in humanized patient-derived xenografts mouse models of triple negative breast cancer

MP51-06 SMYD3 INHIBITION INDUCES PROTECTIVE AUTOPHAGY IN BLADDER CANCER VIA MTOR PATHWAY

Abstract 6138: High Globo-H expression associated with poor survival of gastric cancer patients and enriched PD-L1 expression

3-Phosphoglycerate dehydrogenase: a potential target for cancer treatment

Bibliometric Analysis of Phosphoglycerate Kinase 1 Expression in Breast Cancer and Its Distinct Upregulation in Triple-Negative Breast Cancer

Abstract 1993: Gluthathione Peroxidase 2 Downregulation in the PyMT Mammary Tumor Model Leads to an Aggressive Phenotype Due to Stimulation of Angiogenesis and Tumor Stemness Via HIF1 Alpha Signaling

PHGDH is an Independent Prognosis Marker and Contributes Cell Proliferation, Migration and Invasion in Human Pancreatic Cancer

Abstract 1322: The potential effects of thymidine kinase 1 on breast cancer invasion

Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer

Abstract 4612: Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.